Search 

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.

Xeris is a clinical-stage pharmaceutical company developing patient-friendly injectable drugs for various indications with an initial focus on diabetes. The current paradigm for many injectable drugs is to design formulations for delivery in water-based systems.  However, the presence of water is problematic because it actively degrades many molecules often preventing drug products from being packaged for use as a “ready-to-use” solution.  Xeris' patented and patent-pending XeriSol™ and XeriJect™ formulation technologies are transformative in their elimination of water. By replacing water with non-water, bio-compatible carriers already used in other FDA-approved drugs, Xeris solves a number of problems adding significant value to existing injectable drugs and to new drugs in development.  This technology is already being validated with the development of a non-aqueous glucagon formulation that has shown 24 months of room-temperature stability in solution and very positive safety and efficacy in a Phase 2 clinical study. While this product and other glucagon products are being developed and $20M has been raised to support this development, Xeris is seeking to spinoff its earlier stage non-glucagon assets and obtain funding (both equity and non-dilutive) to support these projects.  More specifically, these projects include the development of a non-aqueous, auto-injectable diazepam to replace the current diazepam rectal gel for treatment of epileptic seizures and a non-aqueous, intradermal auto-injectable epinephrine to replace the current, antiquated EpiPen.